Autolus Therapeutics PLC (NASDAQ:AUTL)
| 2.15 Delayed Data As of Sep 30 |  -0.08 / -3.59%Today’s Change | 1.96 Today|||52-Week Range 7.90 | -58.57% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $183.6M |
Company Description
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.
Contact Information
Autolus Therapeutics Plc The Mediaworks London Greater London W12 7FP |
Employees
Shareholders
| Mutual fund holders | 4.15% |
| Other institutional | 27.19% |
| Individual stakeholders | -- |
Top Executives
| Christian Martin Itin | Chief Executive Officer & Director |
| Christopher Vann | Chief Operating Officer & Senior Vice President |
| Lucinda Crabtree | Chief Financial Officer |
| Martin Pulé | Chief Scientific Officer & Senior Vice President |
| David Brochu | Chief Technical Officer & Senior Vice President |
